$29.15
-0.46-1.55%
Last update: Nov 11, 4:00 PM
Edgewell Personal Care Co
EPCNYSE
Edgewell Personal Care rose 54.2% from $18.91 to $29.15, ahead of the S&P 500's +11.2%. Its worst day was May 14 (−8.5%), and its low came Dec 8 at $15.91.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.68 missed the $0.81 estimate on $537.2M revenue (est. $534.1M); FY revenue guidance of $2.2B–$2.3B against the $2.3B consensus.
−2.7% · S&P 500 −1.7%
Story events cover the past 12 months · Times ET
Edgewell Personal Care closed at its lowest level of the year, 15.9% below where the year started.
−4.9% · S&P 500 −0.3%
EPS of $0.03 beat the $-0.17 estimate on $422.8M revenue (est. $479.1M); FY revenue guidance of $2.2B–$2.3B against the $2.3B consensus.
−4.6% · S&P 500 +0.5%
EPS of $0.60 beat the $0.44 estimate on $519.5M revenue (est. $516.9M); FY revenue guidance of $2.2B–$2.3B against the $2.0B consensus.
−1.9% · S&P 500 +1.4%
Edgewell Personal Care shares fell 8.5%, while the S&P 500 rose 0.8%.
−8.5%, the year's worst day · S&P 500 +0.8%
Edgewell Personal Care shares rose 15.4%, while the S&P 500 fell 1.5%.
+15.4%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 −1.5%
Edgewell Personal Care closed at its highest level of the year, 56.8% above where the year started.
+1.6% · S&P 500 −1.0%
EPS of $0.72 beat the $0.63 estimate on $570.1M revenue (est. $579.0M); FY revenue guidance of $2.3B–$2.3B against the $2.0B consensus.
+2.3% · S&P 500 −0.2%
Edgewell Personal Care shares rose 7.1%, while the S&P 500 fell 1.2%.
+7.1% · S&P 500 −1.2%
Where it ended: a close of $29.15 on Nov 11, 2026. Up next: Q4 2026 earnings on Nov 12, 2026 (EPS est. $0.77, revenue est. $480.0M).
As of the Nov 11, 2026 close
Replay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for EPC and SPY from Benzinga historical bars. Not investment advice.
